Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.34 |
| ▸ | APP | P05067 | 5/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359416 | 0.83 | HRH3 (0.46) | CYP1A2HRH3 | |
| SCHEMBL4550248 | 0.83 | CYP1A2 (0.46) | CYP1A2APPHRH3 | |
| SCHEMBL27648358 | 0.82 | KDM4E (0.33) | CYP1A2HRH3 | |
| SCHEMBL24300560 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP3A4APPPSEN1PSEN2 | |
| SCHEMBL4546643 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP3A4APPPSEN1PSEN2 | |
| SCHEMBL1943559 | 0.78 | HRH3 (0.45) | CYP1A2HRH3RBP4 | |
| SCHEMBL1088328 | 0.77 | USP2 (0.51) | CYP1A2 | |
| SCHEMBL16356926 | 0.76 | HSD17B10 (0.42) | CYP1A2 | |
| SCHEMBL21551733 | 0.75 | RIPK1 (0.36) | — | |
| SCHEMBL23277743 | 0.75 | CYP1A2 (0.42) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127049-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | CYP1A2 54/4885CYP3A4 19/4885APP 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.